Jiuda Zhao

2.1k total citations · 1 hit paper
88 papers, 1.3k citations indexed

About

Jiuda Zhao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jiuda Zhao has authored 88 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 34 papers in Cancer Research. Recurrent topics in Jiuda Zhao's work include Breast Cancer Treatment Studies (23 papers), HER2/EGFR in Cancer Research (18 papers) and Advanced Breast Cancer Therapies (15 papers). Jiuda Zhao is often cited by papers focused on Breast Cancer Treatment Studies (23 papers), HER2/EGFR in Cancer Research (18 papers) and Advanced Breast Cancer Therapies (15 papers). Jiuda Zhao collaborates with scholars based in China, United States and Germany. Jiuda Zhao's co-authors include Feng Du, Guoshuang Shen, Fuxing Zhao, Dengfeng Ren, Fangchao Zheng, Raees Ahmad, Qiuxia Dong, Ziyi Wang, Jinming Li and Binghe Xu and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Annals of Oncology.

In The Last Decade

Jiuda Zhao

81 papers receiving 1.3k citations

Hit Papers

Anlotinib: a novel multi-targeting tyrosine kinase inhibi... 2018 2026 2020 2023 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
    2018 446 citations Guoshuang Shen, Fangchao Zheng et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiuda Zhao China 17 764 573 337 274 214 88 1.3k
Yiyi Yu China 21 741 1.0× 460 0.8× 447 1.3× 327 1.2× 273 1.3× 99 1.4k
Caterina Vivaldi Italy 18 760 1.0× 512 0.9× 346 1.0× 403 1.5× 403 1.9× 101 1.3k
Akira Ooki Japan 20 617 0.8× 456 0.8× 595 1.8× 303 1.1× 331 1.5× 98 1.4k
Shuqiang Yuan China 20 418 0.5× 609 1.1× 423 1.3× 355 1.3× 275 1.3× 70 1.2k
Guoshuang Shen China 14 538 0.7× 356 0.6× 298 0.9× 219 0.8× 144 0.7× 61 1000
Toshihiro Kudo Japan 21 836 1.1× 420 0.7× 533 1.6× 438 1.6× 383 1.8× 86 1.5k
Kazuhiko Yonekura Japan 15 764 1.0× 624 1.1× 474 1.4× 139 0.5× 296 1.4× 23 1.3k
Anwaar Saeed United States 18 964 1.3× 365 0.6× 280 0.8× 198 0.7× 386 1.8× 167 1.4k
Andrea Napolitano Italy 22 486 0.6× 1.1k 2.0× 438 1.3× 330 1.2× 157 0.7× 72 1.9k
Antonella Palazzo Italy 17 724 0.9× 495 0.9× 311 0.9× 349 1.3× 155 0.7× 68 1.2k

Countries citing papers authored by Jiuda Zhao

Since Specialization
Citations

This map shows the geographic impact of Jiuda Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiuda Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiuda Zhao more than expected).

Fields of papers citing papers by Jiuda Zhao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiuda Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiuda Zhao. The network helps show where Jiuda Zhao may publish in the future.

Co-authorship network of co-authors of Jiuda Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Jiuda Zhao. A scholar is included among the top collaborators of Jiuda Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiuda Zhao. Jiuda Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Song, Erwei, Yue Yin, Jiuda Zhao, et al.. (2025). LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2). Annals of Oncology. 36. S1569–S1570. 1 indexed citations
2.
Yang, Ping, et al.. (2025). Risk relationship between six autoimmune diseases and malignancies: An umbrella review. Autoimmunity Reviews. 24(5). 103779–103779.
3.
Li, Yongxin, et al.. (2025). Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database. Expert Opinion on Drug Safety. 1–11. 2 indexed citations
4.
Yang, Ping, Guoshuang Shen, Hengheng Zhang, et al.. (2024). Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis. International Immunopharmacology. 133. 111961–111961. 3 indexed citations
5.
6.
7.
Zhang, Hengheng, Guoshuang Shen, Ping Yang, et al.. (2024). Incidence of antibody–drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 196. 104292–104292. 2 indexed citations
8.
Zhao, Fuxing, Guoshuang Shen, Qiuxia Dong, et al.. (2023). Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy. Journal of Gastroenterology. 58(7). 622–632. 8 indexed citations
9.
Wang, Fengmei, et al.. (2023). Male Breast Cancer: Three Case Reports and a Literature Review. Anti-Cancer Agents in Medicinal Chemistry. 23(19). 2161–2169. 1 indexed citations
10.
Yang, Tao, Jiuda Zhao, Xuejun Wang, et al.. (2023). [Notch1 inhibits the mechanistic role of STING signaling to regulate hepatocyte lipophagy in nonalcoholic steatohepatitis].. PubMed. 31(8). 827–834. 2 indexed citations
11.
Shen, Guoshuang, et al.. (2023). Second-line Endocrine Therapy of Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: A Systematic Review and NetworkMeta-analysis. Current Cancer Drug Targets. 23(9). 718–730. 4 indexed citations
12.
Zheng, Yong‐Hui, Guoshuang Shen, Cheng-Rong Zhang, et al.. (2023). Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis. Clinical and Experimental Medicine. 23(7). 3205–3216. 6 indexed citations
13.
Shen, Guoshuang, Jinming Li, Fuxing Zhao, et al.. (2022). Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis. Clinical and Experimental Medicine. 23(2). 245–254. 7 indexed citations
14.
Zhou, Min, Ping Zhang, Rui Yang, et al.. (2022). A pan-cancer analysis of the expression of STAT family genes in tumors and their relationship to the tumor microenvironment. Frontiers in Oncology. 12. 925537–925537. 7 indexed citations
15.
Shen, Guoshuang, Zhen Liu, Jinming Li, et al.. (2021). Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology. 168. 103530–103530. 13 indexed citations
16.
17.
Zheng, Fangchao, Feng Du, Haili Qian, et al.. (2021). Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer. Biomarker Research. 9(1). 28–28. 23 indexed citations
18.
Ren, Dengfeng, Fangchao Zheng, Junhui Zhao, et al.. (2018). Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study. World Journal of Clinical Cases. 6(10). 373–383. 6 indexed citations
19.
Zhao, Jiuda, Hong Zhao, & Yihebali Chi. (2017). Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. Neuroendocrinology. 106(4). 318–323. 4 indexed citations
20.
Zhang, Shuisheng, Qinglong Jiang, Yajie Zhao, et al.. (2017). Perivascular epithelial cell tumor (PEComa) of the pancreas. Medicine. 96(22). e7050–e7050. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yiyi Yu Breakdown of academic impact, for papers by Caterina Vivaldi Breakdown of academic impact, for papers by Akira Ooki Breakdown of academic impact, for papers by Shuqiang Yuan Breakdown of academic impact, for papers by Guoshuang Shen Breakdown of academic impact, for papers by Toshihiro Kudo Breakdown of academic impact, for papers by Kazuhiko Yonekura Breakdown of academic impact, for papers by Anwaar Saeed Breakdown of academic impact, for papers by Andrea Napolitano Breakdown of academic impact, for papers by Antonella Palazzo
Rankless by CCL
2026